POINT Biopharma Global (PNT) 10-Q2023 Q3 Quarterly report

Filed: 13 Nov 23, 7:15am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Bad

New words: abandoned, abandonment, absent, accelerate, acceleration, adenocarcinoma, AG, al, Allan, allege, alternative, analyst, ankyrin, appraisal, Athebio, Athebody, attention, back, canceled, captioned, challenging, Chancery, cholangiocarcinoma, Clark, complaint, consent, contend, court, DARPin, defense, delivery, demand, depository, devote, discourage, disease, dispose, District, diverted, Division, ductal, Eastern, Eli, employee, entry, exacerbated, exceed, expended, faith, field, frame, FTC, GBq, Ghebremariam, guaranteed, HSR, indemnification, independence, indirect, injunctive, inspect, investigate, ITM, Justice, letter, Lilly, litigation, lower, merit, met, minute, misrepresented, motivate, Munich, negotiate, Notification, notify, occurrence, order, organizational, outlook, Parent, past, pendency, pending, perfected, plaintiff, pm, potent, practice, Premerger, prevent, preventing, proceeding, prohibit, prohibiting, proper, properly, proposal, proposed, proposing, prospective, recoverability, reduction, refuse, registered, repeat, rescission, rescissory, respond, responding, retention, Samson, SE, set, short, sic, Silber, solicit, Southern, stockholder, superior, tender, tendered, text, thereof, thereunder, timeframe, topline, Trinh, unanticipated, underway, untrue, upside, validation, validly, waiting, waived, waiver, warhead, wholly, withdrawn, withholding, York, Yosemite

Removed: chain, disclose, GMP, imaging, molecular, Organization, select, therapeutic, world

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

PNT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of POINT Biopharma Global Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: November 13, 2023	By:	/s/Joe McCann
		Dr. Joe McCann, Ph.D.
		Chief Executive Officer,
		(Principal Executive Officer)


Date: November 13, 2023	By:	/s/Bill Demers
		Bill Demers
		Chief Financial Officer,
		(Principal Financial Officer)

*This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.